Alzheimer's Stigma Hinders Research


A survey of beliefs about Alzheimer’s disease dementia identified the stigmas that pose a hurdle to clinical trials for therapies.

Shana Stites, PsyD

Shana Stites, PsyD

As many as 5 million Americans were living with Alzheimer’s disease (AD) in 2013, according to the Centers for Disease Control and Prevention. This number is projected to rise to 14 million people by 2050, a nearly three-fold increase.

Alzheimer’s disease presents a unique medical challenge, particularly to researchers. It remains the only top 10 cause of disability without a therapy to hinder its progression.

Currently, several trials are trying to develop therapies for AD by 2025. These trials’ success, however, depends upon participants who are willing to undergo genetic and biomarker testing to learn if they are at risk of AD dementia. The stigma surrounding the neurodegenerative disease is a hurdle for clinical trials.

A recent study used online surveys to explore the stigma surrounding AD.

"These are important topics for clinicians to talk about with their patients who either have or are concerned about an Alzheimer’s diagnosis," Shana Stites, PsyD, Perelman School of Medicine, University of Pennsylvania, told MD Magazine. "By understanding what the biggest concerns are about the disease, we can help develop programs and policies to reduce the stigma about Alzheimer's disease."

A sample of 317 adults with a median age of 49 years read and reacted to a fictional vignette of a person with AD dementia. The study randomly assigned participants to 1 of 3 groups for comparison. These groups were based on whether participants were told the person’s condition would worsen, improve, or remain unchanged.

Researchers used a modified version of the Family Stigma in Alzheimer's Disease Scale (FS-ADS) to assess the beliefs, feelings, and expectations of respondents. Participants answered questions about how likely it would be for the vignette character’s health insurance to be limited due to his medical record, due to a result from a brain scan, or due to a result from a genetic test.

"The Genetic Information Nondiscrimination Act of 2008 (GINA) helps to protect against discrimination on the basis of genetic data so this may offer assurance and protection to those who learn their genetic risk of Alzheimer's," said Stites. "But currently there are no policies to offer similar protections for individuals on the basis of a biomarker result. In addition to policies, like GINA, there's a need for programs to educate the public about those policies. In our study, 45% of those surveyed were worried a genetic result could lead to insurance-based discrimination even though this study was conducted years after GINA was created."

The study included questions about the likelihood that the character would face employment discrimination, be excluded from voting or medical decision-making, or exhibit symptoms such as short-term memory loss.

In analyses adjusted for differences between the 3 study groups, over half of participants expected a person with AD dementia would be discriminated against by employers (55.3%; 95% CI, 47.0—65.2) and would be excluded from medical decision-making (55.3%; 95% CI, 46.9–65.4). Many also expressed concern that the person would have health care insurance limited because of data in the medical record (46.6%; 95% CI, 38.0–57.2) or have his health care insurance limited due to a brain imaging result (45.6%; 95% CI, 37.0–56.3).

The most common beliefs were expecting that the person would not remember most recent events (73.8%), would face employment discrimination (55.3%), and would be excluded from medical decision-making (55.3%).

“Public education and policies are needed to address expectations of employment and insurance discrimination related to gene and biomarker risk data,” said the authors. “Studies are needed to understand how advances in diagnosis, testing, and treatment may shift AD stigma and to help position these advances as opportunities to reduce AD stigma.”

The study, “What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the U.S. general public,” was published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Recent Videos
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
Primary Care Roles in Alzheimer Diagnosis, with Theresa Sivers-Teixeira, MSPA, PA-C
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
Depression Screening: Challenges and Solutions at the Primary Care Level
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
© 2024 MJH Life Sciences

All rights reserved.